HK1141812A1 - 基於靶向抗原至抗原呈遞細胞上表達的 的疫苗 - Google Patents

基於靶向抗原至抗原呈遞細胞上表達的 的疫苗

Info

Publication number
HK1141812A1
HK1141812A1 HK10108281.9A HK10108281A HK1141812A1 HK 1141812 A1 HK1141812 A1 HK 1141812A1 HK 10108281 A HK10108281 A HK 10108281A HK 1141812 A1 HK1141812 A1 HK 1141812A1
Authority
HK
Hong Kong
Prior art keywords
dcir
antigen
presenting cells
expressed
vaccines based
Prior art date
Application number
HK10108281.9A
Other languages
English (en)
Inventor
‧祖拉夫斯基
‧班徹羅
Original Assignee
貝勒研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 貝勒研究院 filed Critical 貝勒研究院
Publication of HK1141812A1 publication Critical patent/HK1141812A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pulmonology (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK10108281.9A 2007-02-02 2010-09-01 基於靶向抗原至抗原呈遞細胞上表達的 的疫苗 HK1141812A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88803207P 2007-02-02 2007-02-02
PCT/US2008/052850 WO2008097866A2 (en) 2007-02-02 2008-02-01 Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells

Publications (1)

Publication Number Publication Date
HK1141812A1 true HK1141812A1 (zh) 2010-11-19

Family

ID=39682352

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10108281.9A HK1141812A1 (zh) 2007-02-02 2010-09-01 基於靶向抗原至抗原呈遞細胞上表達的 的疫苗

Country Status (15)

Country Link
US (5) US8057798B2 (zh)
EP (2) EP2527363A1 (zh)
JP (1) JP5377330B2 (zh)
KR (1) KR20090114430A (zh)
CN (1) CN101679508B (zh)
AU (1) AU2008214032B2 (zh)
BR (1) BRPI0807160A2 (zh)
CA (1) CA2715044A1 (zh)
HK (1) HK1141812A1 (zh)
IL (1) IL200088A0 (zh)
MX (1) MX2009008140A (zh)
NZ (2) NZ578696A (zh)
TW (1) TWI446921B (zh)
WO (1) WO2008097866A2 (zh)
ZA (1) ZA200905347B (zh)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
AU2008214077B2 (en) * 2007-02-02 2012-12-13 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
NZ578696A (en) 2007-02-02 2012-01-12 Baylor Res Inst Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2633246A1 (en) 2008-06-19 2009-12-19 Universite Laval Identification of therapeutic agents for hiv infection
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy
CN105837691B (zh) * 2009-03-10 2021-06-29 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
ES2584956T3 (es) 2009-03-10 2016-09-30 Baylor Research Institute Anticuerpos anti-CD40 y usos de los mismos
EP2406290B1 (en) * 2009-03-10 2017-07-05 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
FR2955773B1 (fr) 2010-02-01 2017-05-26 Commissariat A L'energie Atomique Complexe moleculaire de ciblage des antigenes vers les cellules presentatrices d'antigene et ses applications pour la vaccination
WO2011105424A1 (ja) * 2010-02-23 2011-09-01 国立大学法人東京大学 樹状細胞免疫受容体刺激剤
CA2798616A1 (en) * 2010-05-07 2011-11-10 Baylor Research Institute Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20120039916A1 (en) * 2010-08-13 2012-02-16 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
EP3434691A1 (en) 2010-12-01 2019-01-30 AlderBio Holdings LLC Anti-ngf compositions and use thereof
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
AR085573A1 (es) 2011-03-25 2013-10-09 Baylor Res Inst Composiciones y metodos de inmunizacion contra el virus de la hepatitis c
AR086287A1 (es) * 2011-05-05 2013-12-04 Baylor Res Inst Composicion inmunoestimulante, metodo
WO2013076580A2 (en) * 2011-11-23 2013-05-30 Bioven 3 Limited Recombinant proteins and their therapeutic uses
KR101749195B1 (ko) * 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN103045627B (zh) * 2012-11-09 2015-04-15 逢甲大学 于细胞内制造蛋白复合物的方法
CN103409451A (zh) * 2013-06-28 2013-11-27 扬州维克斯生物科技有限公司 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法
AU2014302082B2 (en) 2013-06-28 2019-08-08 Baylor Research Institute Dendritic cell ASGPR targeting immunotherapeutics for multiple sclerosis
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
AU2015233084B2 (en) 2014-02-21 2020-12-17 Anokion Sa Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
AU2015231001A1 (en) 2014-03-21 2016-09-29 Abbvie Inc. Anti-EGFR antibodies and antibody drug conjugates
EP3142691A4 (en) * 2014-05-16 2018-04-11 Baylor Research Institute Methods and compositions for treating autoimmune and inflammatory conditions
TWI724997B (zh) * 2014-08-19 2021-04-21 美商默沙東藥廠 抗ｔｉｇｉｔ抗體
US11000597B2 (en) 2015-01-21 2021-05-11 University Of Florida Research Foundation, Incorporated Engineered receptor/ligand system for delivery of therapeutic agents
JP2018508481A (ja) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
PT3377103T (pt) 2015-11-19 2021-05-26 Revitope Ltd Complementação de fragmento de anticorpo funcional para um sistema de dois componentes para exterminação redirecionada de células indesejadas
WO2017201635A1 (zh) * 2016-05-23 2017-11-30 蔡胜和 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用
BR112018075649A2 (pt) 2016-06-08 2019-04-09 Abbvie Inc. anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
JP6751165B2 (ja) 2016-06-08 2020-09-02 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
CA3027044A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
BR112018075630A2 (pt) 2016-06-08 2019-03-19 Abbvie Inc. anticorpos anti-cd98 e conjugados de fármaco de anticorpo
AU2018224044B2 (en) 2017-02-21 2024-01-25 The Uab Research Foundation Modified AAV capsid proteins and uses thereof
EP3612567B1 (en) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
EP3638296A1 (en) 2017-06-16 2020-04-22 The University Of Chicago Compositions and methods for inducing immune tolerance
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
CN117004573A (zh) * 2017-12-13 2023-11-07 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
CA3094534A1 (en) * 2018-03-19 2019-09-26 Abeome Corporation High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
US11918649B2 (en) 2019-09-18 2024-03-05 Molecular Templates, Inc. PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
EP4031576A1 (en) 2019-09-18 2022-07-27 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) * 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) * 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
EP0693126B9 (en) * 1993-04-02 2007-09-12 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
WO1997034634A1 (en) * 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US7037510B2 (en) * 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
CN100391973C (zh) * 1997-07-09 2008-06-04 先灵公司 分离树突状细胞膜蛋白基因
US20020025315A1 (en) * 1998-01-14 2002-02-28 Naveen N. Anand Chimeric antibodies for delivery of antigens to selected cells of the immune system
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
WO2003033695A1 (fr) * 2001-10-11 2003-04-24 Katakura Industries Co., Ltd. Procede de purification de proteine fusionnee recombinee et procede de production de proteine utilisant ledit procede de purification
CA2468878A1 (en) * 2001-11-30 2003-06-05 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
CN106237316A (zh) * 2006-03-07 2016-12-21 法克斯因内特公司 包含血细胞凝集素的组合物、制造其的方法与使用其的方法
NZ578696A (en) 2007-02-02 2012-01-12 Baylor Res Inst Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
AU2008214077B2 (en) * 2007-02-02 2012-12-13 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
KR101811965B1 (ko) * 2007-11-07 2017-12-22 셀덱스 쎄라퓨틱스, 인크. 인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체

Also Published As

Publication number Publication date
US8449888B2 (en) 2013-05-28
EP2115002A4 (en) 2010-09-01
NZ593450A (en) 2012-08-31
EP2115002B1 (en) 2014-08-20
US9102730B2 (en) 2015-08-11
AU2008214032B2 (en) 2012-06-28
WO2008097866A2 (en) 2008-08-14
CN101679508A (zh) 2010-03-24
JP2010517538A (ja) 2010-05-27
KR20090114430A (ko) 2009-11-03
CN101679508B (zh) 2014-11-05
ZA200905347B (en) 2010-04-28
US20120004643A1 (en) 2012-01-05
EP2115002A2 (en) 2009-11-11
MX2009008140A (es) 2009-10-26
EP2527363A1 (en) 2012-11-28
TW200902061A (en) 2009-01-16
CA2715044A1 (en) 2008-08-14
WO2008097866A3 (en) 2008-12-24
IL200088A0 (en) 2010-04-15
JP5377330B2 (ja) 2013-12-25
US20080241170A1 (en) 2008-10-02
US8057798B2 (en) 2011-11-15
AU2008214032A1 (en) 2008-08-14
US20130295120A1 (en) 2013-11-07
US8586052B2 (en) 2013-11-19
US9234040B2 (en) 2016-01-12
TWI446921B (zh) 2014-08-01
US20120237513A1 (en) 2012-09-20
US20140134168A1 (en) 2014-05-15
NZ578696A (en) 2012-01-12
BRPI0807160A2 (pt) 2018-09-25

Similar Documents

Publication Publication Date Title
HK1141812A1 (zh) 基於靶向抗原至抗原呈遞細胞上表達的 的疫苗
ZA201301013B (en) Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
EP2406290A4 (en) TUMOR VACCINES TREATED ON ANTIGEN PRESENTING CELLS
IL212245A0 (en) Targeting of antigen presenting cells with immunonandtherapeutics
BRPI1009194A2 (pt) vacinas direcionadas à célula apresentadora de antígeno
PL2200646T3 (pl) Szczepionki RNA
ZA201202363B (en) Mycobacterial vaccines
IL222269A (en) Target-targeted pyrolobenzodiazepine couplings
EP2417402A4 (en) Portable heater
EP2356417A4 (en) High temperature transducer using soi electronics
EP2201025A4 (en) FUNCTIONAL LIPID BUILDING PRODUCTS
HK1143532A1 (zh) 使用陽離子脂質體介導的核酸傳送產生免疫反應的方法
WO2011017162A9 (en) Methods for enhancing antigen-specific immune responses
IL211670A (en) Preparations containing therapeutic antibodies against steap-1
GB201211858D0 (en) Walkaway vsp calibrated sonic logs
HRP20180744T1 (hr) Terapeutska cjepiva
GB0801326D0 (en) Vaccines
GB0703219D0 (en) The hybrid strain guage
AU2014201356B2 (en) Combined measles-malaria vaccine
AU2010902225A0 (en) "Biochar-Coke" Produced in an Energy Efficient Manner
AU2009904813A0 (en) Vaccination regimen
AU2008903816A0 (en) Solid antigens
GB0712420D0 (en) Vaccine
GB0707697D0 (en) Vaccine
GB0712435D0 (en) Vaccine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190128